Publications by authors named "Jiying Su"

Claim this Profile
P
Prognostic impact of somatic mutations and additional chromosomal abnormalities in patients with myelodysplastic syndromes and chromosome 20q deletion.
Xinhui Huang, Xiao Li, Qi Liu, Juan Guo, Jianan Chen, Jiying Su

Clin Exp Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Significance of Mutation Spots and Concurrent Gene Mutations on Prognosis and Clinical Outcomes in Myelodysplastic Syndromes With SF3B1 Mutation.
Qi Liu, Fanhuan Xu, Juan Guo, Feng Xu, Xinhui Huang, Jiying Su

Cancer Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinical characteristics, gene mutations and outcomes of myelodysplastic syndromes with diabetes mellitus.
Fanhuan Xu, Jiacheng Jin, Juan Guo, Feng Xu, Jianan Chen, Jiying Su

J Cancer Res Clin Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
deficiency impairs HSPC homeostasis and erythropoiesis via and predicts poor prognosis in MDS.
Jia-Cheng Jin, Bing-Yi Chen, Chu-Han Deng, Jia-Nan Chen, Feng Xu, Ji-Ying Su

Sci Adv· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome.
Xiao Li, Feng Xu, Zheng Zhang, Juan Guo, Qi He, Ji-Ying Su

Clin Epigenetics· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NPM1 mutation with DNMT3A wild type defines a subgroup of MDS with particularly favourable outcomes after decitabine therapy.
Lingyun Wu, Xiao Li, Feng Xu, Dong Wu, Qi He, Jiying Su

Br J Haematol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine.
Cai Xiu, Xiao Li, Lingyun Wu, Feng Xu, Qi He, Jiying Su

J Cancer Res Clin Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dicer1 downregulation by multiple myeloma cells promotes the senescence and tumor-supporting capacity and decreases the differentiation potential of mesenchymal stem cells.
Juan Guo, Youshan Zhao, Chengming Fei, Sida Zhao, Qingqing Zheng, Jiying Su

Cell Death Dis· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway.
Juan Guo, Chengming Fei, Youshan Zhao, Sida Zhao, Qingqing Zheng, Jiying Su

Oncotarget· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome.
Zheng Zhang, Chun-Kang Chang, Qi He, Juan Guo, Ying Tao, Ji-Ying Su

Leuk Lymphoma· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.
Chun-Kang Chang, You-Shan Zhao, Feng Xu, Juan Guo, Zheng Zhang, Ji-Ying Su

Br J Haematol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploration of the role of gene mutations in myelodysplastic syndromes through a sequencing design involving a small number of target genes.
Feng Xu, Ling-Yun Wu, Qi He, Dong Wu, Zheng Zhang, Ji-Ying Su

Sci Rep· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decitabine treatment sensitizes tumor cells to T-cell-mediated cytotoxicity in patients with myelodysplastic syndromes.
Zheng Zhang, Qi He, Ying Tao, Juan Guo, Feng Xu, Ji-Ying Su

Am J Transl Res· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study.
Lingyun Wu, Xiao Li, Chunkang Chang, Feng Xu, Qi He, Jiying Su

Leuk Lymphoma· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic impact of multiparameter flow cytometry immunophenotyping and cytogenetic aberrancies in patients with multiple myeloma.
Juan Guo, Jiying Su, Qi He, Xiao Li, Youshan Zhao

Hematology· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes.
Lingyun Wu, Luxi Song, Lan Xu, Chunkang Chang, Feng Xu, Jiying Su

Tumour Biol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome.
Lingyun Wu, Wenhui Shi, Xiao Li, Chunkang Chang, Feng Xu, Jiying Su

J Transl Med· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromes.
Feng Xu, Ling-Yun Wu, Chun-Kang Chang, Qi He, Zheng Zhang, Ji-Ying Su

Nat Commun· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Feasibility of treatment of cesarean scar pregnancy with dilatation and curettage under ultrasound guidance].
Zhiyi Liang, Jiying Su, Hua Yang

Zhonghua Yi Xue Za Zhi· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis.
Xiao Li, Qiang Song, Yu Chen, Chunkang Chang, Dong Wu, Jiying Su

PLoS One· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishment and validation of an updated diagnostic FCM scoring system based on pooled immunophenotyping in CD34+ blasts and its clinical significance for myelodysplastic syndromes.
Feng Xu, Xiao Li, Chun-Kang Chang, Juan Guo, Ling-Yun Wu, Ji-Ying Su

PLoS One· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Recent advances on the prognostic value of immunophenotyping in multiple myeloma by flow cytometry].
Juan Guo, Chun-Kang Chang, Ji-Ying Su, Xi Zhang, Xiao Li

Zhongguo Shi Yan Xue Ye Xue Za Zhi· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Clinical analysis of neutrophil suppression caused by decitabine for the treatment of myelodysplastic syndromes].
Dong Wu, Xiao Li, Chunkang Chang, Lingyun Wu, Jiying Su

Zhonghua Xue Ye Xue Za Zhi· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine.
Xiao Li, Chunkang Chang, Qi He, Feng Xu, Qingxia Zhang, Jiying Su

Leuk Res· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Current understanding of iron overload hazard in patients with myelodysplastic syndrome].
Lu-Xi Song, Ji-Ying Su, Zhen Zhang, Chun-Kang Chang

Zhongguo Shi Yan Xue Ye Xue Za Zhi· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis